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Background: Acute kidney injury is a common complication of liver transplantation. In this single-centre
retrospective observational study, we investigated the impact of acute kidney disease on liver recipient survival.
Methods: The study population consisted of patients who underwent a liver engraftment between January 2002
and November 2006, at a single transplantation centre in São Paulo, Brazil. Acute kidney injury diagnosis and
staging were according to the recommendations of the Acute Kidney Injury Network and consisted of scanning the
daily serum creatinine levels throughout the hospital stay. Patients requiring renal replacement therapy prior to
transplantation, those who developed acute kidney injury before the procedure or those receiving their second
liver graft were excluded from the study.
Results: A total of 444 liver transplantations were performed during the study period, and 129 procedures (29%)
were excluded. The remaining 315 patients constituted the study population. In 207 procedures, the recipient was
male (65%). The mean age of the population was 51 years. Cumulative incidence of acute kidney injury within 48 h,
during the first week after transplantation, and throughout the hospital stay was 32, 81 and 93%, respectively. Renal
replacement therapy was required within a week after the transplantation in 31 procedures (10%), and another 17
(5%) required replacement therapy after that period. Mean follow-up period was 2.3 years. Time in days from acute
kidney injury diagnosis to initiation of replacement therapy or reaching serum creatinine peak was associated with
lower overall survival even when adjusted for significant potential confounders (HR 1.03; 95% CI 1.01, 1.05; p=0.002).
Overall, patients experiencing acute kidney injury lasting for a week or more before initiation of replacement
therapy experienced a threefold increase in risk of death (HR 3.02; 95% CI 2.04, 4.46; p<0.001).
Conclusions: Acute kidney injury after liver transplantation is remarkably frequent and has a substantial impact on
patient survival. Delaying the initiation of renal replacement therapy in such population may increase mortality by
more than 20% per day.Background
Liver transplantation (LT) is the therapy of choice for
individuals with advanced chronic liver disease and those
with acute liver failure [1]. Patients undergoing LT often
suffer from some degree of renal dysfunction [2]. During
the perioperative period of LT, they face additional insults
to the kidney, such as haemorrhage, administration of* Correspondence: marcelocbatista@uol.com.br
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reproduction in any medium, provided the ornephrotoxic drugs and frequently massive infusion of blood
products [3].
Although kidney injury is often reversible, it brings
ominous consequences including increased length of
hospitalization, time on mechanical ventilation and rate
of infection, and progression to chronic renal failure,
increasing the total cost of the procedure and directly
contributing to a lower liver graft and patient survival [4].
The results of previous studies conducted in transplant-
ation recipients to identify risk factors for developing
acute kidney injury (AKI), are not easy to generalize to
daily practice given the wide variation in definitions of
kidney injury, as well as the periods analysed. The seriesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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employ the more modern and recommended diagnostic
criteria [5].
Several recent studies have suggested that early renal re-
placement therapy (RRT) improves prognosis in patients
who develop AKI [6-9]. Whether these findings are related
to the effects of RRT itself, the duration of AKI episode, or
the fact that some of the patients started on dialysis earlier
would have recovered kidney function and would not
require dialysis at all remains debatable.
Considering the high incidence of AKI and the high
number of RRT procedures in LT recipients, we proposed
this observational study to evaluate the impact of time
from AKI onset to RRT initiation or creatinine peak on
survival of patients undergoing LT.
Methods
This study was approved by the Ethics in Research Com-
mittee of the Federal University of São Paulo (Protocol
number 0358/08). Data were collected from a sequential
series of liver transplants performed at the Hospital
Israelita Albert Einstein (HIAE) from January 2002 to
November 2006 from living and deceased donors. This
analysis was limited to this time frame to avoid selection
bias, related to the introduction of MELD (Model for
End-stage Liver Disease) allocation criteria. Cases taken
as urgent, such as patients with acute liver failure or
graft primary nonfunction, were prioritized and received
the first suitable organ available within the state area
[10]. All transplantation recipients were admitted to the
intensive care unit (ICU) in the immediate postoperative
period. Transplantation organ allocation at the time of
the study was ordered chronologically [11].
Data collection
Based on a prospectively maintained clinical research
database, originally developed by the LT surgical team,
the medical records for patients undergoing LT from
2002 to 2006 were retrospectively reviewed to retrieve
hospitalization data, including baseline demographic
characteristics and co-morbid conditions, preoperative
clinical and laboratory data, indications of LT, liver
disease stage according to the Child-Pugh score, and
intraoperative variables including liver graft donor type,
surgical time, and total ischaemia period.
A single surgical team from the hepatology group
of HIAE, all specifically trained in LT, performed all
procedures. The immunosuppressive regimen consisted
of a calcineurin inhibitor (cyclosporine predominantly
until 2005, later tacrolimus), an antiproliferative drug
and a corticosteroid. Whole blood levels of those drugs
were measured by fluorescence polarization immunoassay.
Postoperative variables included the development of
sepsis, need for pressor drugs, use of well-recognizednephrotoxic agents, including radiocontrast agents, non-
steroidal anti-inflammatory drugs, and antimicrobials
(vancomycin, aminoglycosides, polymyxin B and ampho-
tericin B). The Acute Physiology and Chronic Health
Evaluation (APACHE) II score was determined at the time
of admission to the ICU. MELD score was calculated
according to the equation described by Kamath and
coworkers [12]. Sepsis was defined according to the
international consensus definition [13]. Severe liver graft
dysfunction included primary nonfunction and graft
dysfunctions with a score higher than 7 in the Gonzales
criteria for liver failure [14].
AKI was defined according to the Acute Kidney Injury
Network (AKIN) recommendations [15]. Exact dates of
AKI event and stage reached in seven days were obtained
by computerized scanning of the results of daily laboratory
tests for serum creatinine and 24-h urinary output from
the electronic medical record system for each procedure
on the database, which was divided by four and two, to
represent 6-h and 12-h urinary output, respectively. RRT
was initiated at the discretion of the nephrology staff,
based on common clinical indications such as hypervolemia,
hyperkalaemia, refractory acidosis, uremic signs or symp-
toms, and/or anuria. All attending nephrologists were part
of the same team. The procedure report module of the
electronic medical record system was used to identify
patients who required RRT, and the dates on which they
underwent RRT. Patients who developed AKI before LT
or required RRT prior to LT were excluded from this
analysis, as well as those receiving simultaneous kidney
and liver graft or who underwent liver retransplantation.
The main predictor variable of interest for the primary
outcome was the time from AKI diagnosis to either initi-
ation of RRT or to creatinine peak for those who did not
require RRT. Secondary predictors evaluated were time
from each of the AKI stages to RRT or creatinine peak.
The primary outcome in this analysis was patient
death after LT from any cause.
Statistical analysis
Numerical variables were described by median and inter-
quartile range, and categorical variables by absolute and rela-
tive frequencies. For comparison of baseline characteristics
regarding the main predictor variable, univariable analysis
was performed with the chi-squared test and Mann–
Whitney U test for categorical and continuous variables,
respectively, and the results are shown under p value in
Tables 1 and 2.
Univariable analysis was performed to identify additional
variables associated with primary outcome as potential
confounders, with each variable in the database entered
into a Cox Proportional Hazards Model as a single
covariate with the time to patient’s death as dependent
variable. A log minus log plot for each variable was used
Table 1 Baseline and intraoperative characteristics of the liver transplantation cohort stratified by time from AKI to
RRT or serum creatinine peak
Time from AKI onset to RRT or SCr peak
Less than a week (N = 221) A week or more (N = 94) Totals (N=315) p value
Age (years) 53 (46 – 60) 53 (45 – 58) 53 (46 – 60) 0.502
Weight (kg) 72 (62 – 81) 72 (60 – 82) 72 (62 – 82) 0.538
Height (cm) 169 (162 – 174) 168 (160 – 175) 169 (162 – 174) 0.446
Men 148 (67%) 59 (63%) 207 (66%) 0.472
Diabetes mellitus 42 (19%) 23 (24%) 65 (21%) 0.273
Hypertension 16 (7%) 8 (8%) 24 (8%) 0.697
Smoking habit 10 (4%) 1 (1%) 11 (4%) 0.126
eGFR (MDRD) 92 (74 – 113) 96 (76 – 110) 93 (74 – 112) 0.508
Previous serum creatinine (mg/dl) 0.8 (0.7 – 1.0) 0.8 (0.7 – 1.0) 0.8 (0.7 – 1.0) 0.385
Serum albumin (mg/dl) 3.1 (2.7 – 3.4) 3.1 (2.8 – 3.5) 3.1 (2.7 – 3.5) 0.100
Total bilirubin (mg/dl) 2.6 (1.7 – 4.1) 2.4 (1.6 – 3.8) 2.6 (1.7 – 4.0) 0.419
Main Indication for LT
Hepatitis B 22 (10%) 12 (13%) 34 (11%) 0.462
Hepatitis C 110 (50%) 48 (51%) 158 (50%) 0.834
Alcoholic cirrhosis 55 (25%) 21 (22%) 76 (24%) 0.629
Acute liver failure 6 (19%) 3 (3%) 9 (3%) 0.816
Liver malignancy 48 (22%) 27 (29%) 75 (24%) 0.182
Other cirrhotic 43 (19%) 18 (19%) 61 (19%) 0.950
MELD score 14 (10 – 18) 12 (9 – 15) 13 (9 – 17) 0.067
Child-Pugh stage 0.075
A 32 (14%) 22 (23%) 54 (17%)
B 110 (50%) 48 (51%) 158 (50%)
C 79 (36%) 24 (26%) 103 (33%)
Deceased liver donor 126 (57%) 55 (58%) 181 (58%) 0.806
Piggyback technique 214 (97%) 92 (98%) 306 (97%) 0.612
Total ischemia time (h) 6.6 (2.4 – 10) 6.9 (2.5 – 10) 6.7 (2.4 – 10) 0.716
Surgical time (h) 7.8 (7 – 8.5) 7.5 (7 – 8.5) 7.6 (7 – 8.5) 0.405
Blood products (units) 4 (2 – 9) 3 (1 – 5) 4 (2 – 8) 0.027
Aprotinin 65 (29%) 18 (19%) 83 (26%) 0.059
Intraoperative pressor 20 (9%) 5 (5%) 25 (8%) 0.262
APACHE II score 15 (13 – 19) 16 (14 – 19) 16 (13 – 19) 0.243
AKI: acute kidney injury; APACHE: Acute Physiology and Chronic Disease Health Evaluation; eGFR: estimated glomerular filtration rate; LT: liver transplantation;
MDRD: Modification of Diet in Renal Disease; MELD: Model for End Stage Liver Disease; RRT: renal replacement therapy; SCr: serum creatinine.
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variables with a p value <0.1 in univariable analysis were
subsequently entered into a multivariable model. Time
in days from AKI diagnosis and time from each AKI
stage to RRT or creatinine peak were entered into a final
multivariable model with other confounder variables
associated with primary outcome as covariates.
A receiver operator characteristic (ROC) curve relating
time from AKI to RRT or creatinine peak with mortalitywas obtained to identify the optimal cut-off value for
conversion of continuous variables into categorical ones,
and patients were grouped according the cut-off points
of days analyzed by ROC curve. This categorical variable
was adjusted for the same factors as the previous model.
The same model was applied to a subset of patients who
required RRT after LT.
All tests were performed using the statistical software
SPSS version 17.0 (SPSS, Chicago, IL).
Table 2 Postoperative characteristics and outcomes of the liver transplantation cohort stratified by time from AKI to
RRT or serum creatinine peak
Time from AKI onset to RRT or SCr peak
Less than a week (N = 221) A week or more (N = 94) Total (N = 315) p value
Postoperative pressor drugs 41 (19%) 13 (14%) 54 (17%) 0.309
Nephrotoxic drugs 150 (68%) 60 (64%) 210 (67%) 0.486
Sepsis 82 (37%) 38 (40%) 120 (38%) 0.579
Tacrolimus initially 145 (66%) 80 (85%) 225 (71%) <0.001
Surgical re-intervention 54 (24%) 33 (35%) 87 (28%) 0.053
Severe graft failure 52 (24%) 26 (28%) 78 (25%) 0.437
AKI stage reached 0.005
No AKI 22 (10%) 0 (0%) 22 (7%)
1 109 (55%) 42 (45%) 151 (48%)
2 59 (30%) 36 (38%) 95 (30%)
3 31 (16%) 16 (17%) 47 (15%)
Required RRT 35 (16%) 13 (14%) 48 (15%) 0.650
Received CRRT 17 (8%) 9 (10%) 26 (8%) 0.579
In-hospital mortality 12 (5%) 8 (8%) 20 (6%) 0.305
Overall mortality 40 (18%) 34 (36%) 74 (24%) 0.001
AKI: acute kidney injury; CRRT: continuous renal replacement therapy; LT: liver transplantation; RRT: renal replacement therapy; SCr: serum creatinine.
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Population demographics and outcomes
During the study period, 444 procedures were performed.
Of those, 106 had met AKI criteria before LT; in 16 LT,
the recipient had already received a previous liver graft,
5 procedures were simultaneous kidney/liver transplants
and in 2 other LT, the patients were on the chronic RRT
program prior to LT. These 129 LT (29%) were excluded
from analysis. The remaining 315 LT were performed in
315 patients, who represented the study population.
Baseline and postoperative characteristics are listed in
Tables 1 and 2.
Severe AKI, requiring RRT occurred after 48 procedures
(15%), of which 31 (10%) were within the first week after
transplantation with a median of 3 (3–7) days. Another
17 (5%) required RRT after that period with a median of
15 (10–21) days. Continuous RRT (CRRT) was the ini-
tial therapy for 26 (8.3%) procedures, CRRT only in 11
of them (3.5%), and followed by intermittent haemodi-
alysis in 15 (4.8%). Intermittent haemodialysis alone was
the therapy of choice for 22 (7%) patients. All patients
requiring RRT fulfilled criteria for the AKI before the
initiation of therapy. Mortality rate for those requiring
RRT after LT was 58% (n=28), while for those not re-
quiring it was only 17% (n=46) (OR 6.7; 95% CI 3.49,
12.96; p<0.001).
Mortality rates observed in the hospital, up to 90 days
and up to 1 year after LT were 6.3% (n=20), 10% (n=32)
and 18% (n=56), respectively. The overall mortality rate
was 24% (n=74) after a mean period of 1488 days or4.1 years. All cases alive at the end of the follow-up were
censured on April 1st, 2007.
Mortality risk factors
Time from diagnosis of AKI to RRT or creatinine peak
was significantly associated with the primary endpoint
(p<0.05). In multivariable analysis, AKI to RRT or cre-
atinine peak (hazard ratio [HR] 1.03; 95% CI 1.01, 1.05;
p=0.003), remained significant even after adjustment for
other risk factors associated with the primary outcome.
By generating a ROC curve with mortality as the
dependent variable, the optimal cut-off value for days
from AKI to RRT or creatinine peak was determined to
be seven days after AKI onset. The resulting categorical
variable with this cut-off discriminated mortality with a
sensitivity and specificity of 44% and 77%, respectively,
giving an area under the curve of 0.607.
Baseline and postoperative variables grouped by the
interval between AKI diagnosis to RRT initiation or
creatinine peak greater or equal to or less than 7 days
for cohort subset analysed with respective p values are
shown in Tables 1 and 2.
The adjusted categorical predictor for main confounders
remained strongly associated with higher risk of death
(HR 3.02; 95% CI 2.04, 4.46; p<0.001). This association
remained unchanged even after adjustment for each clin-
ically relevant or statistically significant confounder for
all procedures in this cohort (Figure 1), as well as when
analysing only those patients requiring RRT (Table 3).
This group of patients experienced a nearly threefold
Figure 1 Cox regression survival curve. Adjusted survival curve for whole cohort grouped by days to RRT or creatinine peak; p<0.001.
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every confounder.
Moreover, using continuous time from the beginning
of each AKI stage to RRT or creatinine peak, as second-
ary predictors, while adjusting for the same confounders,
we found a successively higher HR. HR transformations
revealing the time that doubles the risk of death is
shown in Table 4.
Discussion
AKI is well recognized for its impact on the evolution of
critically ill patients. In the various severity scores such
as the APACHE II and Sequential Organ Failure Assess-
ment score, AKI alone is responsible for 15-20% of the
total score weight [16]. The diversity of definitions isTable 3 Associations of predictors with primary outcome (mo
Predictor
A week or more from diagnosis of AKI to RRT or SCr peak
Unadjusted
Adjusted for age, gender, diabetes, hypertension, smoking habit and liver
Adjusted for age, gender, diabetes, hypertension, smoking habit, liver mal
postoperative pressor drugs and severe liver graft failure
A week or more from AKI to RRT only, adjusted1
Days from AKI diagnosis to RRT or creatinine peak adjusted
Days from AKI stage 1 to RRT or creatinine peak adjusted
Days from AKI stage 2 to RRT or creatinine peak adjusted
Days from AKI stage 3 to RRT or creatinine peak adjusted
AKI: acute kidney injury; CI: confidence interval; HR: hazard ratio; RRT: renal replacem
required RRT after LT.responsible for large discrepancies in AKI incidence and
mortality [17]. Using the AKIN criteria, we observed a
high incidence of renal dysfunction within the first 48 h
after LT, requiring RRT in 20% of the cases. Most RRT
were performed within the first week after transplant-
ation. The incidence of AKI after LT described in the
literature is quite wide, with reports ranging from 8.3
to 61% [4,18]. Lafayette described 27 cases of AKI
(23%) in 115 liver transplants, which were associated
with longer stay in the ICU, higher risk of infection,
and higher cost and in-hospital mortality (46% in group
AKI vs. 9% of patients without AKI) [19]. The overall
rate observed in this series was higher than in other
similar works, due to criteria used to define AKI. In-
hospital mortality was substantially lower than thatrtality)
HR 95% CI P-value
3.11 1.92, 5.05 <0.001
malignancy 3.03 1.84, 4.98 <0.001
ignancy, total surgical time, 3.68 2.16, 6.26 <0.001
2.93 1.17, 7.30 0.021
1.03 1.01, 1.05 0.002
1.03 1.01, 1.05 0.002
1.19 1.10, 1.28 <0.001
1.18 1.08, 1.30 0.001
ent therapy; SCr: serum creatinine; 1 model applied only to patients who
Table 4 Time to double risk of death according to AKI
stage reached
AKI stage HR Time in days to double the risk of death 95% CI
Stage 1 1.03 23 14 – 70
Stage 2 1.19 4 3 – 7
Stage 3 1.18 4 3 – 9
AKI: acute kidney injury; CI: confidence interval; HR: hazard ratio.
Narciso et al. BMC Nephrology 2013, 14:43 Page 6 of 8
http://www.biomedcentral.com/1471-2369/14/43reported in that study for both groups, which suggests
that there may have been technical improvements in
hospital care after the publication of that study.
In the general population developing AKI in the
absence of hyperkalaemia or hypervolemia, the threshold
for blood urea nitrogen (BUN) or creatinine for RRT initi-
ation remains subjective, and no additional benefit is
associated with earlier initiation of therapy [20]. It has also
been argued that earlier initiation of RRT could mean
exposure to the risks of therapy in patients who would
regain renal function with conservative therapy alone
Also, intradialytic hypotension episodes may delay re-
covery of renal function and adversely impact patient
survival [21]. Several studies over the last decade have
evaluated the impact of time of initiation of RRT on the
outcome of AKI in the general population. Gettings and
colleagues analysed the time of initiation of CRRT on
the outcome in patients with posttraumatic AKI and
stratified 100 consecutive patients based on BUN at
baseline [22]. Survival was 39% in the “early” initiation
group compared to 20% in the “late” group. Neverthe-
less, RRT has been frequently reported as an independ-
ent predictor of mortality [23]. These findings have
been often evoked to delay RRT initiation, as if RRT
itself were responsible for higher death rate. In fact,
according to these findings, each day of delaying RRT
initiation increases the risk of death from 3% to 19%.
In studying 1238 patients, distributed in three different
groups: early (<2 days), delayed (2–5 days) or late (>5 days)
RRT initiation after ICU admission, Bagshaw and
coworkers observed greater mortality in the late group.
The same held true when comparing the creatinine
levels on RRT initiation, that is, no assumptions
regarding time of exposure to AKI could be made [7].
The study of Andrade and coworkers also supports early
intervention as being beneficial in a population of
patients developing AKI after leptospirosis infection,
comparing intensive and promptly initiated therapy
versus less intensive and delayed therapy, intensive
group performed better, but the study did not take into
account the exposure period to severe stages of AKI
[24]. Payen and colleagues evaluated the effects of ex-
cessive positive fluid balance on 60-day mortality, the
mention of early vs. late RRT initiation refers to time in
days since ICU admission, and again, no assumptionscould be made regarding AKI exposure period [25].
Ostermann compared patients initiating RRT before
reaching AKI stage 3 with patients who did not reach
that stage prior to RRT initiation. Their cut-offs were
set for the period before RRT after ICU admission, regard-
less of AKI stage, or time from AKI stage 3, no matter
how long the patient had been exposed to milder
AKI stages.
Coca and colleagues retrospectively studied the dur-
ation of AKI episodes in more than 35,000 diabetic
patients undergoing noncardiac surgery in multiple US
centres and found higher durations associated with
increased risk of long-term mortality [26]. According to
these authors, an AKI episode occurred when the patient
met at least AKI stage 1 criteria or was on RRT, leading
to overestimation of AKI episode duration, and RRT ex-
posure was equivalent to AKI exposure, which may not
hold true in most situations.
One could argue this analysis should be limited to
patients who need RRT [27]. When analysing the RRT
subgroup only, the association of mortality with longer
time of AKI onset to therapy was still significant, but the
theoretical main predictor was, in fact, the exposure
period to AKI, and we considered the exposure period
of AKI onset to RRT initiation to be the same as AKI
onset to creatinine peak. Although a crude marker of
kidney function, the creatinine peak was used to indicate
the beginning of kidney function recovery, and conse-
quent reduction of the effects of AKI exposure, similarly
to RRT initiation. This approach is backed up by litera-
ture findings implicating small rises in creatinine to the
increase in mortality [28]. At least one study found that
mortality rates are similar whether the patient has an
increase or a decrease in serum creatinine levels of
0.3 mg/dl or more during the study period [29]. Al-
though the published AKIN criteria specify an absolute
increase of ≥0.3 mg/dL within 48 h, the authors applied
the criteria without specifying the direction of change,
as they classified patients with falling creatinine values
as having AKI as well. The authors considered that to
be related to the fact that few, if any, interventions are
able to improve renal function and consequently lower
serum creatinine levels, if it is chronically reduced,
and therefore, any improvement found over short
periods of time could be related to a previous episode
of AKI [29]. Even though the validity of such equiva-
lence (RRT initiation vs. kidney function recovery) is
debatable regarding the effect magnitude, one must
consider the much lower side effects of kidney func-
tion recovery when compared to RRT side effects.
Literature evidence suggests that there is excess mor-
tality independently attributed to AKI itself, and one of
the possible explanations for that is the effect of uremic
toxins on the patient’s homeostasis and inflammatory
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exposure to AKI would increase their effects and mortal-
ity. Considering that, RRT was used only to censure such
period, as serum creatinine measurements after RRT initi-
ation would no longer reflect the patient’s glomerular
filtration rate and/or severity of kidney injury.
As is the case with past observational studies on this
topic, this study was not able to address the issue of
whether the association of earlier RRT initiation with
improved outcomes is related to the fact that some
of the patients started on dialysis earlier would have
recovered kidney function and would not have required
dialysis at all, since the inclusion of such patients in the
“early” initiation group may result in improved outcomes.
We minimized that issue by including patients who
recovered kidney function without RRT. Hardly any
evidence in this field has come from non-observational
studies. Even in the only available randomized con-
trolled trial, no strong conclusion could be drawn, since
early versus late was defined by the urinary output ver-
sus biochemical values [32]. While the real impact of
early versus late initiation of dialysis would only be
justified when, at the moment patients fulfilled the criteria
for dialysis, one group started RRT while the other group
was kept under clinical treatment for a longer period. Even
so, other confounders may arise, as an intention-to-treat
approach must be employed to avoid the ethical dilemma
of not treating potentially fatal conditions in the group
randomized for clinical treatment.
Furthermore, our study design was not able to control
for other unrecorded confounders, but when we applied
a propensity score for every possible confounder we had
in our database. The resultant Cox model for mortality,
with the propensity score for a longer AKI exposure,
demonstrated a week of exposure to AKI effects had an
even higher HR (data not shown).
In spite of these limitations but considering that most
of the previous observational studies lacked common
criteria to identify AKI, that they did not employ mod-
ern criteria to define AKI within a narrow timeframe as
recommended by AKIN group, and they were usually
limited to an AKI population requiring RRT, most of
them too critically ill to experience any benefit from any
therapy, we took a different approach. Instead of study-
ing early versus late RRT initiation time, we decided to
study the effect of time of exposure to AKI episodes
throughout the whole hospital stay, regardless of the
need for RRT, which was initiated on the basis of clinical
criteria. We demonstrated that regardless of AKI stage
reached, patients developing AKI lasting 7 days or
longer, before beginning of recovery or initiation of RRT,
have a threefold risk of dying, reflecting the impact of
exposure period to kidney injury on patient’s outcome.
By applying the inverse transformation to obtain the HRfrom this categorical predictor, we found that each day
of delay in RRT initiation increases the risk of death by
20%, with a twofold increase in risk of dying occurring
after 4 days of AKI onset.
Conclusions
In conclusion, our findings suggest a higher mortality
in LT recipients with longer exposure period to AKI,
especially for those reaching AKI stage 2 or 3 with AKI
episodes lasting longer than four days. In such group,
lack of recovery of kidney function or initiation of RRT
seems to double the risk of death. Whether these
findings translate well into clinical practice requires
additional evaluation such as a randomized controlled
trial. Delaying RRT initiation seems to be unjustifiable,
especially in this population where absolute RRT indications
may take longer to occur.
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